Lilly's Olomorasib Receives U.S. FDA's Breakthrough Therapy Designation for the Treatment of Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer
RegulatorypositiveolomorasibPositive
AI Analysis
Summary
Eli Lilly announced that olomorasib received FDA Breakthrough Therapy designation as a monotherapy for treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer. This regulatory designation accelerates the development pathway for the drug candidate.
Outcome Details
Breakthrough Therapy designation granted
Importance:8/10
Sentiment:
0.80
breakthrough_designationFDAKRAS_G12Cpancreatic_cancermonotherapy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 3, 2026 7:08 PM